MedTrace Logo

Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome

NCT03271866 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-04-11

No results posted yet for this study

Summary

In this study, the investigators will investigate the impact and the related mechanism of metformin treatment on cognitive impairment of schizophrenia with a high risk of metabolic syndrome. Patients will be randomized to the metformin group or non-metformin control group (40 patients per arm) for 24 weeks. Clinical assessment will be done at screen/baseline, 4 weeks, 12 weeks, and 24 weeks. The specific aims are to compare the metformin group versus controls on 1) clinical core symptoms; 2) cognition. Biological samples also will be collected, and stored to research related mechanisms.

Conditions

Interventions

DRUG

metformin

metformin 1500mg per day

Sponsors & Collaborators

  • Central South University

    lead OTHER

Principal Investigators

  • Tiannan Shao, M.D., Ph.D. · Central South University

  • Dongyu Kang, M.D. · Central South University

  • Renrong Wu, M.D., Ph.D. · Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03271866 on ClinicalTrials.gov